Science · 1992 · 32 citations · 23 references
MedicineNeurobiologyNeuroscienceNeurochemistryNeurodegenerationNeuropharmacologyDopaminergic PharmacologyDopaminergic SignalingNeuroprotectionNeurotransmitter MetabolismParkinson DiseaseParkinsonian DisordersDopaminergic NeurodegenerationDopaminergic NeuronsDopaminergic PathwaysParkinson's Disease PharmacotherapyParkinson’s Disease PharmacotherapyParkinson’s Disease TreatmentRodent NeuropharmacologyStriatal Dopamine Function
A parkinsonian syndrome can be produced in nonhuman primates by administration of the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Parkinsonian-like symptoms induced acutely by MPTP were ameliorated after treatment with G M1 ganglioside, a substance shown to have neurotrophic effects on the damaged dopamine system in rodents. Treatment with G M1 ganglioside also increased striatal dopamine and metabolite levels and enhanced the dopaminergic innervation of the striatum as demonstrated by tyrosine hydroxylase immunohistochemistry. These results suggest that G M1 ganglioside may hold promise as a therapeutic agent for the treatment of Parkinson's disease.
23
Rate of cell death in parkinsonism indicates active neuropathological process
Patrick L. McGeer, Shigeru Itagaki, Haruhiko Akiyama et al. · Annals of Neurology · 1988 · 563 citations
Epidemiology of parkinsonism: Incidence, classification, and mortality
Ali H. Rajput, Kenneth P. Offord, C. Mary Beard et al. · Annals of Neurology · 1984 · 340 citations